
|Videos|September 19, 2016
When Should Patients Switch from Statins to PCSK9 Inhibitors?
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.
Advertisement
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5


























